---
title: Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes
nct_id: NCT05971667
overall_status: UNKNOWN
phase: PHASE2, PHASE3
sponsor: Beni-Suef University
study_type: INTERVENTIONAL
primary_condition: IVF
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05971667.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05971667"
ct_last_update_post_date: 2023-08-03
last_seen_at: "2026-05-12T07:19:26.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes

**Official Title:** "Effect of Tadalafil, Sildenafil and Pentoxyfylline on Endometrial Thickness and Frozen Embryo Transfer Outcomes

**NCT ID:** [NCT05971667](https://clinicaltrials.gov/study/NCT05971667)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Beni-Suef University
- **Conditions:** IVF
- **Start Date:** 2023-07-30
- **Completion Date:** 2023-10-30
- **CT.gov Last Update:** 2023-08-03

## Brief Summary

The aim of this study is to investigate the Effect of different vasodilators as Tadalafil, Sildenafil and pentoxyfylline in In vitro Fertilization. In addition, the thickness of endometrium and pregnancies rates of these women will also be examined. All adverse effects of all drugs will be estimated

## Detailed Description

A prospective randomized clinical study will be conducted in the IVF clinic of the gynecology department of Beni Suef University Hospital, Beni-Suef, Egypt. The study will These patients will be randomized into four groups.

The participants will take drugs starting from the end of menstruation cycle till endometrium reach optimal and then will start progesterone 800 mg daily.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 40 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* women having thawed embryos

Exclusion Criteria:

* hypotension
* cardiovascular, hepatic, and renal diseases;
* uncontrolled diabetes mellitus;
* ovarian cysts;
* hyperprolactinemia;
* abnormal thyroid functions;
* uterine fibroids;
* patients taking nitrates;
* endometriosis and adenomyosis
```

## Arms

- **tadalafil** (EXPERIMENTAL) — tadalafil 10 mg one tablet daily
- **pentoxifylline** (EXPERIMENTAL) — pentoxyfilline 400 mg two tabs daily
- **sildenafil** (EXPERIMENTAL) — sildenafil 20 mg two tablets
- **control group.** (NO_INTERVENTION) — no intervention is given

## Interventions

- **tadalafil** (DRUG) — tadalafil 10 mg one tablet daily
- **Sildenafil** (DRUG) — sildenafil 20 mg two tablets daily
- **pentoxifylline** (DRUG) — pentoxifylline 400 mg two tabs daily

## Primary Outcomes

- **endometrial thickness** _(time frame: within 16 day of menstruation)_ — measured by transvaginal ultrasound

## Secondary Outcomes

- **pregnancy rate** _(time frame: 1 month)_

## Locations (1)

- Beni-suef university Hospital, Banī Suwayf, Beni Suweif Governorate, Egypt

## Recent Field Changes (last 30 days)

- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.beni-suef university hospital|banī suwayf|beni suweif governorate|egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05971667.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05971667*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*